Glaukos Corporation GKOS reported fourth-quarter 2024 adjusted loss of 40 cents per share, narrower than the Zacks Consensus Estimate of a loss of 43 cents. The figure also improved from the year-ago...
As the fourth-quarter earnings season progresses, this week will be crucial for many companies in the medical device sector. According to the latest Earnings Preview report, the Medical sector is poised...
Gilbert H Kliman, a director at $GKOS ($GKOS), sold 2,000 shares of the company on 12-11-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 5.8% of their shares....
Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern.Shares of this Zacks Rank #2 (Buy)...
The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.61%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.60%. US stock indexes this morning...
The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.54%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.42%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.51%. US stock indexes this morning...